Skip to content

United Therapeutics UTHR Income Statement

Q1 '26Q4 '25Q3 '25Q2 '25Q1 '25
$781.5M-1.1%$790.2M-1.2%$799.5M+0.1%$798.6M+0.5%$794.4M+7.9%
$133.4M+29.0%$103.4M+2.5%$100.9M+15.2%$87.6M-5.3%$92.5M+21.9%
$648.1M-5.6%$686.8M-1.7%$698.6M-1.7%$711M+1.3%$701.9M+6.3%
82.9%-4.0pp86.9%-0.5pp87.4%-1.7pp89%+0.7pp88.4%-1.3pp
$138.2M-0.9%$139.5M+9.4%$127.5M-4.9%$134M-10.1%$149M+11.4%
$184.1M-3.4%$190.6M+4.4%$182.6M-14.1%$212.5M+24.9%$170.1M+0.9%
$455.7M+5.1%$433.5M+5.5%$411M-5.3%$434.1M+5.5%$411.6M+8.8%
$325.8M-8.7%$356.7M-8.2%$388.5M+6.6%$364.5M-4.8%$382.8M+7.0%
41.7%-3.5pp45.1%-3.5pp48.6%+3.0pp45.6%-2.5pp48.2%-0.4pp
$3M-3.2%$3.1M+3.3%$3M-58.9%$7.3M+19.7%$6.1M-22.8%
-$7.5M-109%$87.3M+76.4%$49.5M+12.8%$43.9M+7.9%$40.7M+4.9%
$318.3M-28.3%$444M+1.4%$438M+7.2%$408.4M-3.6%$423.5M+6.8%
$43.4M-45.5%$79.7M-19.7%$99.3M+0.4%$98.9M-2.4%$101.3M+6.4%
$274.9M-24.5%$364.3M+7.6%$338.7M+9.4%$309.5M-3.9%$322.2M+6.9%
35.2%-10.9pp46.1%+3.7pp42.4%+3.6pp38.8%-1.8pp40.6%-0.4pp
$5.82-24.3%$7.69+7.4%$7.16+11.7%$6.41-3.3%$6.63+6.8%
$348.4M-8.2%$379.5M-7.5%$410.4M+6.4%$385.6M-4.2%$402.6M+6.7%
44.6%-3.4pp48%-3.3pp51.3%+3.0pp48.3%-2.4pp50.7%-0.6pp
$325.8M-8.7%$356.7M-8.2%$388.5M+6.6%$364.5M-4.8%$382.8M+7.0%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

What is United Therapeutics's revenue?
United Therapeutics (UTHR) generated $3.2B in revenue over the trailing twelve months, up 5.9% year over year.
Is United Therapeutics profitable?
United Therapeutics reported $1.3B in net income over the trailing twelve months, a 40.6% net margin.
What are United Therapeutics's profit margins?
Gross margin is 86.6% and operating margin is 45.3%, with a 40.6% net margin.
What is United Therapeutics's earnings per share?
United Therapeutics's diluted EPS over the trailing twelve months is $27.08.
Where does United Therapeutics's income statement data come from?
Every line is extracted from United Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.